Page 293 - Drug Class Review

Drug Effectiveness Review Project
Alzheimer classification: Mild-to-moderate
Groups similar at baseline: Yes

Health Outcome Measures: NR 0.057)

tacrine placebo 74.0 73.6 58.3 48.6 100 100 0.71 0.66 17.3 15.8 Primary Outcome Measures: CASI; CGIC; IQCODE Secondary Outcome Measures: MMSE; ADS; CGIC rated by caregivers Timing of assessments: Baseline and every 6 weeks Intermediate Outcome Measures: Significantly more improvement on the CASI for TAC compared to placebo (P = 0.05)* No significant differences in patient or caregiver rated CGIC (P > 0.5)* No significant differences in IQCODE between TAC and placebo (P > 0.5)* Marginally significant improvement in MMSE for TAC-treated pa

• • • • • •

Final Report Update 1 Authors: Wong et al. Year: 1999 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity (% Chinese): Other germane population qualities: Baseline HIS • Baseline MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs